Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y4BO
|
|||
| Former ID |
DIB007804
|
|||
| Drug Name |
ABI-013
|
|||
| Synonyms |
Nab-CY196; Nab-ABI-139; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Abraxis; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Celgene
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Preclinical | [1] | |
| Company |
Abraxis BioScience Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin (TUB) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Celgene Corporation. | |||
| REF 2 | Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Research. 01/2011; 70(8 Supplement):2617-2617. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.